These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22964698)

  • 61. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
    Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
    Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
    Rosano GMC; Vitale C; Volterrani M
    Cardiovasc Drugs Ther; 2016 Aug; 30(4):393-398. PubMed ID: 27417323
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antiarrhythmic properties of ranolazine--from bench to bedside.
    Tzeis S; Andrikopoulos G
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1733-41. PubMed ID: 22916846
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ranolazine: a new approach to management of patients with angina.
    Tafreshi MJ; Fisher E
    Ann Pharmacother; 2006 Apr; 40(4):689-93. PubMed ID: 16595572
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anti-anginal and anti-ischemic effects of late sodium current inhibition.
    Wimmer NJ; Stone PH
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):69-77. PubMed ID: 23247666
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis.
    Belsey J; Savelieva I; Mugelli A; Camm AJ
    Eur J Prev Cardiol; 2015 Jul; 22(7):837-48. PubMed ID: 24776376
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention.
    Pelliccia F; Pasceri V; Marazzi G; Rosano G; Greco C; Gaudio C
    Am Heart J; 2012 Jun; 163(6):1019-23. PubMed ID: 22709755
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosis.
    Athauda-Arachchi P; Lang C
    Cardiovasc Ther; 2012 Aug; 30(4):e210-1. PubMed ID: 21884008
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Introduction: Managing patients with chronic angina: emerging therapeutic options for improving clinical efficacy and outcomes.
    Rumsfeld JS
    J Manag Care Pharm; 2006 Oct; 12(8 Suppl):S2-3. PubMed ID: 23577421
    [No Abstract]   [Full Text] [Related]  

  • 70. Chronic angina: new medical options for treatment.
    McCullough PA
    Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
    Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ranolazine: an anti-anginal drug with further therapeutic potential.
    Reffelmann T; Kloner RA
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):319-29. PubMed ID: 20222810
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
    Rousseau MF; Pouleur H; Cocco G; Wolff AA
    Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Skene A; McCabe CH; Braunwald E;
    Am Heart J; 2006 Jun; 151(6):1186.e1-9. PubMed ID: 16781216
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
    Minotti G
    J Pharmacol Exp Ther; 2013 Sep; 346(3):343-9. PubMed ID: 23818683
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In regard to the TERISA trial.
    Golwala H
    J Am Coll Cardiol; 2014 Jul; 64(4):420. PubMed ID: 25060380
    [No Abstract]   [Full Text] [Related]  

  • 77. [Symptomatic coronary heart disease therapy: ranolazine reduces frequency of angina in diabetic patients].
    MMW Fortschr Med; 2013 Mar; 155 Spec No 1(1):20. PubMed ID: 24260912
    [No Abstract]   [Full Text] [Related]  

  • 78. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.
    Scirica BM; Morrow DA; Budaj A; Dalby AJ; Mohanavelu S; Qin J; Aroesty J; Hedgepeth CM; Stone PH; Braunwald E
    J Am Coll Cardiol; 2009 Apr; 53(16):1411-21. PubMed ID: 19371824
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis.
    Ayyasamy L; Bagepally BS
    Clin Ther; 2023 May; 45(5):458-465. PubMed ID: 37087299
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reply: In regard to the TERISA trial.
    Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Yue P; Ben-Yehuda O; Belardinelli L; Chaitman BR
    J Am Coll Cardiol; 2014 Jul; 64(4):420-1. PubMed ID: 25060381
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.